Outcomes and Prognostic Factors in Patients with EGFR Mutant Metastatic Non-Small Cell Lung Cancer Who Treated with Erlotinib
İ DOĞAN, N Khanmammadov… - Clinical Cancer …, 2022 - avesis.istanbul.edu.tr
… results in our study, in a retrospective study, the median OS was found as 34 months in
patients with mNSCLC with exon 19 mutation who were used with erlotinib and gefitinib, while it …
patients with mNSCLC with exon 19 mutation who were used with erlotinib and gefitinib, while it …
Evaluating the Efficacy of EGFR-TKIs Combined With Radiotherapy in Advanced Lung Adenocarcinoma Patients With EGFR Mutation: A Retrospective Study
Y Wang, W Yu, J Shi, R Qiu, N Jiang… - … in Cancer Research …, 2022 - journals.sagepub.com
… EGFR-TKI combination is 250 mg gefitinib once a day, 150 mg erlotinib once a day, 125 mg
… A retrospective multicenter study by Bi N et al 9 showed that first-line TKI combined with RT …
… A retrospective multicenter study by Bi N et al 9 showed that first-line TKI combined with RT …
Retrospective Analysis of the Incidence of Drug-Induced Interstitial Lung Disease by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Survival in …
M Ishibashi, Y Nakagawa, T Shimizu, Y Gon… - JMA journal, 2023 - jstage.jst.go.jp
… and erlotinib and to prolong progression-free survival. However, only a … study (1). The
NEJ003 and JO22903 studies have suggested that the efficacy and safety of gefitinib and erlotinib …
NEJ003 and JO22903 studies have suggested that the efficacy and safety of gefitinib and erlotinib …
[HTML][HTML] EGFR variant allele frequency predicts EGFR-TKI efficacy in lung adenocarcinoma: a multicenter study
B Gieszer, Z Megyesfalvi, V Dulai, J Papay… - … Cancer Research, 2021 - ncbi.nlm.nih.gov
… were included in this multi-center, retrospective study, who … were included who received either
gefitinib or erlotinib as first- or … Another limitation of our study is its retrospective nature with …
gefitinib or erlotinib as first- or … Another limitation of our study is its retrospective nature with …
Nationwide real-world cohort study of first-line tyrosine kinase inhibitor treatment in epidermal growth factor receptor-mutated non–small-cell lung cancer
RGP Gijtenbeek, RAM Damhuis, HJM Groen… - Clinical lung cancer, 2020 - Elsevier
… with then regularly available TKIs (gefitinib, erlotinib or afatinib). … its retrospective and
non-interventional nature, this study … erlotinib, we observed a poorer adjusted survival for gefitinib …
non-interventional nature, this study … erlotinib, we observed a poorer adjusted survival for gefitinib …
… of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study
B Bilgin, MAN Sendur, S Yucel, E Celik… - … of Cancer Research …, 2021 - Springer
… bias due to the retrospective design of our study and Korean study. … erlotinib/gefitinib arm
is the other limitation of our study. Despite all of these limitations, this study is one of the studies …
is the other limitation of our study. Despite all of these limitations, this study is one of the studies …
[HTML][HTML] EGFR exon 18 mutations in advanced non-small cell lung cancer: A real-world study on diverse treatment patterns and clinical outcomes
H Xu, G Yang, W Li, J Li, X Hao, P Xing, Y Yang… - Frontiers in …, 2021 - frontiersin.org
… This retrospective, single-center study was analyzed in 82 advanced NSCLC patients …
generally tended to be resistant to gefitinib or erlotinib. An in vitro study in cell lines also showed a …
generally tended to be resistant to gefitinib or erlotinib. An in vitro study in cell lines also showed a …
… vs gefitinib alone in untreated EGFR-mutant non–small cell lung cancer in patients with brain metastases: the GAP BRAIN open-label, randomized, multicenter, phase …
X Hou, M Li, G Wu, W Feng, J Su, H Jiang… - JAMA Network …, 2023 - jamanetwork.com
… study reported that erlotinib combined with bevacizumab had a similar percentage of EGFR
T790M mutation with erlotinib alone … A multicenter retrospective study reported that up-front …
T790M mutation with erlotinib alone … A multicenter retrospective study reported that up-front …
The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer
… a retrospective cohort study using data from the claims database of Taipei Veterans General
Hospital to perform direct comparisons of these three EGFR-TKIs (gefitinib, erlotinib, and …
Hospital to perform direct comparisons of these three EGFR-TKIs (gefitinib, erlotinib, and …
Phase III clinical trial for the combination of erlotinib plus ramucirumab compared with osimertinib in previously untreated advanced or recurrent non–small cell lung …
N Haratake, H Hayashi, M Shimokawa, Y Nakano… - Clinical lung cancer, 2022 - Elsevier
… the FLAURA study revealed that osimertinib did not significantly prolong overall survival (OS)
compared with gefitinib or erlotinib in patients with the L858R. The RELAY study revealed …
compared with gefitinib or erlotinib in patients with the L858R. The RELAY study revealed …